## ABSORICA LD<sup>®</sup> (isotretinoin) Clinical Awareness Resource and Education C-A-R-E™ Program: Treatment and Patient Monitoring Chart for Healthcare Professionals for Acne Therapy

DISCLAIMER: This material was developed by Sun Pharmaceutical, as part of the risk minimization plan for ABSORICA LD. This material is not intended for promotional use.

Patient Name:		Treatment Start Date:s file for monitoring reference.				
	Pretreatment Considerations	At Initiation of Treatment (Start of Month 1)	Start of Month 2	Start of Month 3	Start of Month 4	
Patient Assessment (Rate % acne improvement over pretreatment)		25% 50% 75% 100%	25% 50% 75% 100%	25% 50% 75% 100%	25% 50% 75% 100%	
Dosage	The initial dose of ABSORICA LD should be individualized according to the patient's weight and severity of the disease. Note that transient exacerbation of acne is occasionally seen during this initial period  A complete course of therapy consists of 15 to 20 weeks of ABSORICA LD administration  Please consult Product Monograph for complete dosage and administration instructions	Usual dose range is between 0.4 to 0.8 mg/kg body weight daily  ABSORICA LD may be taken with or without meals, as a single daily dose or in 2 divided doses  ABSORICA LD should be taken in the nearest number of whole capsules, either as a single dose or in 2 divided doses during the day, whichever is more convenient. To decrease the risk of esophageal irritation, instruct patients to take the capsules with a full glass of liquid  For females, treatment should start on the second or third day of the next normal menstrual period following the second negative pregnancy test	The dose should be adjusted between 0.4 and 0.8 mg/kg body weight daily. In exceptional instances, dosage may be adjusted up to 1.6 mg/kg/day depending upon individual patient response and tolerance to the drug.  ABSORICA LD may be taken with or without meals, as a single daily dose or in 2 divided doses  ABSORICA LD should be taken in the nearest number of whole capsules, either as a single dose or in 2 divided doses during the day, whichever is more convenient. To decrease the risk of esophageal irritation, instruct patients to take the capsules with a full glass of liquid  Dosage depends on individual patient response and tolerance to the drug  Review any side effects and adjust dosage as required	The dose should be adjusted between 0.4 and 0.8 mg/kg body weight daily. In exceptional instances, dosage may be adjusted up to 1.6 mg/kg/day depending upon individual patient response and tolerance to the drug.  ABSORICA LD may be taken with or without meals, as a single daily dose or in 2 divided doses  ABSORICA LD should be taken in the nearest number of whole capsules, either as a single dose or in 2 divided doses during the day, whichever is more convenient. To decrease the risk of esophageal irritation, instruct patients to take the capsules with a full glass of liquid  Dosage depends on individual patient response and tolerance to the drug  Review any side effects and adjust dosage as required	The dose should be adjusted between 0.4 and 0.8 mg/kg body weight daily. In exceptional instances, dosage may be adjusted up to 1.6 mg/kg/day depending upon individual patient response and tolerance to the drug.  ABSORICA LD may be taken with or without meals, as a single daily dose or in 2 divided doses  ABSORICA LD should be taken in the nearest number of whole capsules, either as a single dose or in 2 divided doses during the day, whichever is more convenient. To decrease the risk of esophageal irritation, instruct patients to take the capsules with a full glass of liquid  Dosage depends on individual patient response and tolerance to the drug  Review any side effects and adjust dosage as required	
Female patients only	Use effective contraception without any interruption for 1 month before beginning ABSORICA LD therapy     Two reliable forms of contraception should be used simultaneously (at least one being a primary method), even by female patients who normally do not employ contraception due to infertility, who are not sexually active, or who have amenorrhea     Two negative serum or urine pregnancy tests before starting ABSORICA LD therapy     Treatment should start on the second or third day of the next normal menstrual period following the second negative pregnancy test     Review the C-A-R-E Program     No breastfeeding during treatment	Patient confirms having used effective contraception without any interruption during ABSORICA LD therapy  Two reliable forms of contraception should be used simultaneously (at least one being a primary method), even by female patients who normally do not employ contraception due to infertility, who are not sexually active, or who have amenorrhea  Before renewal of prescription, obtained confirmation from patient of negative serum or urine pregnancy test made no more than 1 week before prescription renewal visit  Review the C-A-R-E Program  No breastfeeding during treatment	Patient confirms having used effective contraception without any interruption during ABSORICA LD therapy  Two reliable forms of contraception should be used simultaneously (at least one being a primary method), even by female patients who normally do not employ contraception due to infertility, who are not sexually active, or who have amenorrhea  Before renewal of prescription, obtained confirmation from patient of negative serum or urine pregnancy test made no more than 1 week before prescription renewal visit  Review the C-A-R-E Program  No breastfeeding during treatment	Patient confirms having used effective contraception without any interruption during ABSORICA LD therapy  Two reliable forms of contraception should be used simultaneously (at least one being a primary method), even by female patients who normally do not employ contraception due to infertility, who are not sexually active, or who have amenorrhea  Before renewal of prescription, obtained confirmation from patient of negative serum or urine pregnancy test made no more than 1 week before prescription renewal visit  Review the C-A-R-E Program  No breastfeeding during treatment	Confirms having used effective contraception without any interruption during ABSORICA LD therapy and has been warned to continue to do so for 1 month after treatment ends  Two reliable forms of contraception should be used simultaneously (at least one being a primary method), even by female patients who normally do not employ contraception due to infertility, who are not sexually active, or who have amenorrhea  Before renewal of prescription, obtained confirmation from patient of negative serum or urine pregnancy test made no more than 1 week before prescription renewal visit and reminded patient to also do such a test at 1 month after discontinuation of treatment  Review the C-A-R-E Program  No breastfeeding during treatment and for 1 month after discontinuation of treatment	





## Warnings and Precautions

	Pretreatment Considerations	At Initiation of Treatment (Start of Month 1)	Start of Month 2	Start of Month 3	Start of Month 4
Warnings and	Do not donate blood or blood products	Complete lab testing 1 week prior to visit	Complete lab testing 1 week prior to visit	Complete lab testing 1 week prior to visit	Complete lab testing 1 week prior to visit
Precautions	Do not share ABSORICA LD with other people	Do not donate blood or blood products	Do not donate blood or blood products	Do not donate blood or blood products	Do not donate blood or blood products until at least 1 month after ABSORICA LD therapy
	Do not take antibiotics (such as tetracyclines) unless discussed with doctor	Do not share ABSORICA LD with other people	Do not share ABSORICA LD with other people	Do not share ABSORICA LD with other people	ends  • Do not share ABSORICA LD with
	Do not take vitamin A	Do not take antibiotics (such as tetracyclines)	<ul> <li>Do not take antibiotics (such as tetracyclines)</li> </ul>	<ul> <li>Do not take antibiotics (such as tetracyclines)</li> </ul>	other people
	<ul><li>supplements</li><li>Use sun protection and avoid</li></ul>	unless discussed with doctor	unless discussed with doctor	unless discussed with doctor	Do not take antibiotics (such as tetracyclines) unless discussed with doctor
	artificial UV lights	<ul> <li>Do not take vitamin A supplements</li> </ul>	<ul> <li>Do not take vitamin A supplements</li> </ul>	<ul> <li>Do not take vitamin A supplements</li> </ul>	• Do not take vitamin A
	Abstain from/minimize alcohol consumption	Use sun protection and avoid artificial UV lights	Use sun protection and avoid artificial UV lights	Use sun protection and avoid artificial UV lights	<ul><li>use sun protection and avoid</li></ul>
	<ul> <li>Do not use exfoliative anti-acne agents or have cosmetic procedures to</li> </ul>	Abstain from/minimize alcohol consumption	Abstain from/minimize alcohol consumption	Abstain from/minimize alcohol consumption	artificial UV lights     Abstain from/minimize
	smooth the skin such as waxing, aggressive chemical dermabrasion, cutaneous	Do not use exfoliative anti-acne agents or have	Do not use exfoliative anti-acne agents or have	Do not use exfoliative anti-acne agents or have	<ul><li>alcohol consumption</li><li>Do not use exfoliative</li></ul>
	laser procedures, or wax epilation until 5 to 6 months after the end of treatment	cosmetic procedures to smooth the skin such as waxing, aggressive chemical	cosmetic procedures to smooth the skin such as waxing, aggressive chemical	cosmetic procedures to smooth the skin such as waxing, aggressive chemical	anti-acne agents or have cosmetic procedures to smooth the skin such as
	Do not take St. John's wort	dermabrasion, cutaneous laser procedures, or wax epilation until 5 to 6 months	dermabrasion, cutaneous laser procedures, or wax epilation until 5 to 6 months	dermabrasion, cutaneous laser procedures, or wax epilation until 5 to 6 months	waxing, aggressive chemical dermabrasion, cutaneous laser procedures, or wax
	<ul> <li>Avoid strenuous physical activity or vigorous exercise</li> </ul>	after the end of treatment  • Do not take St. John's wort	after the end of treatment  • Do not take St. John's wort	after the end of treatment  • Do not take St. John's wort	epilation until 5 to 6 months after the end of treatment
	Do not drive at night until you know if ABSORICA LD has	Avoid strenuous physical	Avoid strenuous physical	Avoid strenuous physical	Do not take St. John's wort
	affected your vision     Do not change between	<ul><li>activity or vigorous exercise</li><li>Do not drive at night until</li></ul>	activity or vigorous exercise     Do not drive at night until	<ul> <li>activity or vigorous exercise</li> <li>Do not drive at night until</li> </ul>	<ul> <li>Avoid strenuous physical activity or vigorous exercise</li> </ul>
	ABSORICA LD and other isotretinoin products. ABSORICA LD is not the same	you know if ABSORICA LD has affected your vision	you know if ABSORICA LD has affected your vision	you know if ABSORICA LD has affected your vision	<ul> <li>Do not drive at night until you know if ABSORICA LD has affected your vision</li> </ul>
	as other isotretinoin products	<ul> <li>Do not change between ABSORICA LD and other</li> </ul>	Do not change between ABSORICA LD and other	Do not change between ABSORICA LD and other	Do not change between
	<ul> <li>Do not use ABSORICA LD for a condition for which it was not prescribed</li> </ul>	isotretinoin products. ABSORICA LD is not the same as other isotretinoin products	isotretinoin products. ABSORICA LD is not the same as other isotretinoin products	isotretinoin products. ABSORICA LD is not the same as other isotretinoin products	ABSORICA LD and other isotretinoin products ABSORICA LD is not the same as other isotretinoin products
	Do not take low-dose birth control pills that contain progesterone only	Do not use ABSORICA LD for a condition for which it was not prescribed	Do not use ABSORICA LD for a condition for which it was not prescribed	Do not use ABSORICA LD for a condition for which it was not prescribed	Do not use ABSORICA LD for a condition for which it was not prescribed
	Do not take corticosteroids such as hydrocortisone, prednisolone, etc	Do not take low-dose birth control pills that contain progesterone only	Do not take low-dose birth control pills that contain progesterone only	Do not take low-dose birth control pills that contain progesterone only	Do not take low-dose birth control pills that contain progesterone only
	. Do not take phonytoin	p. 28222.2	F. 2022212113 21113	P. 080000.0113	2.080000.03

 Do not take corticosteroids such as hydrocortisone,

prednisolone, etc

• Do not take phenytoin

 Do not take corticosteroids such as hydrocortisone,

prednisolone, etc

• Do not take phenytoin

• Do not take corticosteroids

such as hydrocortisone,

prednisolone, etc

Do not take phenytoin

UV, ultraviolet.

• Do not take phenytoin

• Do not take corticosteroids such as hydrocortisone,

prednisolone, etc

• Do not take phenytoin



## **Blood Monitoring**

	Pretreatment Considerations	At Initiation of Treatment (Start of Month 1)	Start of Month 2	Start of Month 3	Start of Month 4
Blood monitoring	Complete blood count	Complete blood count	Complete blood count	Complete blood count	Complete blood count
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	Blood sugar (diabetics)	Blood sugar (diabetics)	Blood sugar (diabetics)	Blood sugar (diabetics)	Blood sugar (diabetics)
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	Urine or serum pregnancy	Urine or serum pregnancy	Urine or serum pregnancy	Urine or serum pregnancy	Urine or serum pregnancy
	Negative	Negative	Negative	Negative	Negative
	Positive	Positive	Positive	Positive	Positive
	Lipids	Lipids	Lipids	Lipids	Lipids
	Triglycerides*	Triglycerides*	Triglycerides*	Triglycerides*	Triglycerides*
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	Cholesterol	Cholesterol	Cholesterol	Cholesterol	Cholesterol
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	HDL	HDL	HDL	HDL	HDL
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	LDL	LDL	LDL	LDL	LDL
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	Liver Function	Liver Function	Liver Function	Liver Function	Liver Function
	ALT	ALT	ALT	ALT	ALT
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	AST	AST	AST	AST	AST
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	ALP	ALP	ALP	ALP	ALP
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal
	Renal Function	Renal Function	Renal Function	Renal Function	Renal Function
	Normal	Normal	Normal	Normal	Normal
	Abnormal	Abnormal	Abnormal	Abnormal	Abnormal

ALT, alanine transaminase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

<sup>\*</sup>There have been some reports of acute pancreatitis, which is known to be potentially fatal. This is sometimes associated with elevation of serum triglycerides in excess of 800 mg/dL or 9 mmol/L. Therefore, every attempt should be made to control significant triglyceride elevation. ABSORICA LD should be discontinued if uncontrolled hypertriglyceridemia or symptoms of pancreatitis occur. Abnormalities of serum triglycerides, HDL, and cholesterol were reversible upon cessation of oral isotretinoin therapy.





## Side-Effect Management

	Pretreatment Considerations	At Initiation of Treatment (Start of Month 1)	Start of Month 2	Start of Month 3	Start of Month 4
Serious side-effect management  For other possible side effects, please consult the Product Monograph for information.		Side-effect counselling  Serious side effects*  Mental health problems such as depression or psychosis  Liver problems  Pancreatitis  Intestine (bowel) problems  Bone and muscle problems  Allergic reactions  Benign intracranial hypertension  Hearing and vision problems  Heart problems  Pregnancy issues during or after treatment  Problems with blood sugar levels  Serious skin reactions such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)	Side-effect counselling  Serious side effects*  Mental health problems such as depression or psychosis  Liver problems  Pancreatitis  Intestine (bowel) problems  Bone and muscle problems  Allergic reactions  Benign intracranial hypertension  Hearing and vision problems  Heart problems  Pregnancy issues during or after treatment  Problems with blood sugar levels  Serious skin reactions such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)	Side-effect counselling  Serious side effects*  Mental health problems such as depression or psychosis  Liver problems  Pancreatitis  Intestine (bowel) problems  Bone and muscle problems  Allergic reactions  Benign intracranial hypertension  Hearing and vision problems  Heart problems  Pregnancy issues during or after treatment  Problems with blood sugar levels  Serious skin reactions such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)	Side-effect counselling  Serious side effects*  Mental health problems such as depression or psychosis  Liver problems  Pancreatitis  Intestine (bowel) problems  Bone and muscle problems  Allergic reactions  Benign intracranial hypertension  Hearing and vision problems  Heart problems  Pregnancy issues during or after treatment  Problems with blood sugar levels  Serious skin reactions such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
Nuisance side-effect management	Side-effect counselling  Common side effects*  Chapped lips  Dryness of lining of nose  Dry skin or itching  Arthralgia  Myalgia  Other	Side-effect counselling  Common side effects*  Chapped lips  Dryness of lining of nose  Dry skin or itching  Arthralgia  Myalgia  Other	Side-effect counselling  Common side effects*  Chapped lips  Dryness of lining of nose  Dry skin or itching  Arthralgia  Myalgia  Other	Side-effect counselling  Common side effects*  Chapped lips  Dryness of lining of nose  Dry skin or itching  Arthralgia  Myalgia  Other	Side-effect counselling  Common side effects*  Chapped lips  Dryness of lining of nose  Dry skin or itching  Arthralgia  Myalgia  Other
Suggested treatments for nuisance side effects	<ul> <li>Dryness of lining of nose: Apply nasal lubricant</li> <li>Arthralgia: Treat with acetaminophen or NSAIDs</li> <li>Chapped lips: Apply a lip balm</li> <li>Exacerbation of acne is usually transient</li> <li>Dry skin or itching: Apply a water-based moisturizer</li> <li>Dryness of eyes: Use an artificial tears product</li> </ul>				
Other considerations	Questions for patients Mood swings?  Yes No Depression?  Yes No	Questions for patients Mood swings?  Yes No Depression?  Yes No	Questions for patients Mood swings?  Yes No Depression?  Yes No	Questions for patients Mood swings?  Yes No Depression?  Yes No	Questions for patients Mood swings?  Yes No Depression?  Yes No

NSAIDs, nonsteroidal anti-inflammatory drugs.

\*Other possible side effects—please consult the Product Monograph for information.



